Fosfomycin as antibiotic prophylaxis in men undergoing transrectal prostate biopsy: a systematic review of the literature

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Transrectal prostate biopsy remains the standard method for prostate cancer diagnosis, but it is associated with a high risk of infectious complications. In recent years, fosfomycin has been increasingly used as an alternative for antibiotic prophylaxis due to the increasing resistance of pathogens to fluoroquinolones, its good safety profile and ease of use. Results of several studies dedicated to the efficiency of fosfomycin are highlighted in this review. Fosfomycin demonstrates significant advantages as a drug for the prevention of infectious and inflammatory complications in patients after prostate biopsy, especially in case of increasing resistance to fluoroquinolones. Its efficacy, safety and ease of use make it an attractive choice and a reliable alternative in the context of increasing antibiotic resistance. Combination regimens with fluoroquinolones may be preferable for high-risk group.

Full Text

Restricted Access

About the authors

A. N. Bernikov

FGBOU VO “Russian University of Medicine”; Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Author for correspondence.
Email: bernikov@mac.com
ORCID iD: 0000-0001-8361-585X

Ph.D., associate professor at the Department of Urology, urologist

Russian Federation, Moscow; Moscow

A. V. Govorov

FGBOU VO “Russian University of Medicine”; Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Email: dr.govorov@gmail.com
ORCID iD: 0000-0003-3299-0574

Ph.D., MD, professor at the Department of Urology, Head of the Department of Oncourology

Russian Federation, Moscow; Moscow

Z. A. Bagateliya

Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin

Email: bagateliaz@mail.ru
ORCID iD: 0000-0001-5699-3695

Ph.D., MD, professor, First Deputy Director

Russian Federation, Moscow

References

  1. Cornford P., Tilki D., van den Bergh R.C.N., Briers E., Patient Advocate (European Prostate Cancer Coalition/Europa UOMO), D. Eberli, G. De Meerleer, M. De Santis, S. Gillessen, A.M. Henry, G.J.L.H. van Leenders, J. Oldenburg, I.M. van Oort, D.E. Oprea-Lager, G. Ploussard, M. Roberts, O. Rouvière, I.G. Schoots, J. Stranne, T. Wiegel Guidelines Associates: T. Van den Broeck, O. Brunckhorst, A. Farolfi, G. Gandaglia, N. Grivas, M. Lardas, M. Liew, E. Linares Espinós, P-P.M. Willemse Guidelines Office: J. Darraugh, E. Smith, N. Schouten. EAU - EANM - ESTRO -ESUR - ISUP – SIOG Guidelines on Prostate Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris April 2024. ISBN 978-94-92671-23-3.
  2. Roberts M.J., Bennett H.Y., Harris P.N., Holmes M., Grummet J., Naber K., Wagenlehner F.M. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017;104:11–21. doi: 10.1016/j.urology.2016.12.011.
  3. Cai T., Gallelli L., Cocci A., Tiscione D., Verze P., Lanciotti M., Vanacore D., Rizzo M., Gacci M., Saleh O., et al. Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: Fosfomycin trometamol, an attractive alternative. World J. Urol. 2017;35:221–228. doi: 10.1007/ s00345-016-1867-6.
  4. Fahmy A.M., Kotb A., Youssif T.A., Abdeldiam H., Algebaly O., Elabbady A. Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study. Arab. J. Urol. 2016;14:228–233. doi: 10.1016/j.aju.2016.05.003.
  5. Kisa E., Altug M.U., Gurbuz O.A., Ozdemir H. Fosfomycin: A good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors. Int. Braz. J. Urol. 2017;43:1068–1074. doi: 10.1590/s1677-5538.ibju.2016.0619.
  6. Delory T., Goujon A., Masson-Lecomte A., Arias P., Laurancon-Fretar A., Bercot B., Mongiat-Artus P., Molina J.-M., Lafaurie M. Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study. Int. J. Infect. Dis. 2021;102:269–274. doi: 10.1016/j.ijid.2020.10.065.
  7. Gu H.M., Gu J.S., Chung H.S., Jung S.I., Kwon D., Kim M.H., Jung J.H., Han M.A., Kang S.J., Hwang E.C., Dahm P. Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2023;59(5):911. doi: 10.3390/medicina59050911.
  8. Bjerklund Johansen T.E., Kulchavenya E., Lentz G.M. Livermore D.M., Nickel J.C., Zhanel G., Bonkat G. Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. Eur Urol Focus. 2022;8(5):1483-1492. doi: 10.1016/j.euf.2021.11.007. Epub 2021 Dec 15.
  9. Roberts M.J., Scott S., Harris P.N., Naber K., Wagenlehner F.M.E., Doi S.A.R. Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol. 2018;36(3):323–330. doi: 10.1007/s00345-017-2163-9. Epub 2017 Dec 29.
  10. Noreikaite J., Jones P., Fitzpatrick J., Amitharaj R., Pietropaolo A., Vasdev N., Chadwick D., Somani B.K., Rai B.P. Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21(2):153–160. doi: 10.1038/s41391-018-0032-2. Epub 2018 Feb 27.
  11. Lim D.G., Jung S.I., Hwang E.C., Kim T.H., Bae S., Huh J.S., Lee S.J., Chung H., Choi H. Effectiveness of fosfomycin-based antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: A Korean multicenter study. Investig Clin Urol. 2023;64(3):289–295. doi: 10.4111/icu.20220413.
  12. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Perepanova T.S., Kozlov R.S., «DARMIS-2018» Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study «DARMIS-2018». Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):134–146. Russian. (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С., исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134–146. doi: 10.36488/cmac.2019.2.134-146).
  13. Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinyakova L.A., Palagin I.S. Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. M., 2022. pp. 107-108. Russian (Перепанова Т.С., Козлов Р.С., Руднов В.А., Синякова Л.А., Палагин И.С. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М., 2022. С. 107–108).
  14. Cardoso A., Ribeiro J., Araújo R., Torres J.P., Mota P. The Efficacy of Fosfomycin as Antibiotic Prophylaxis for Transrectal Prostate Biopsy and Impact on Lower Urinary Tract Symptom After Biopsy: A Prospective Study. Urol Res Pract. 2023;49(4):259–265. doi: 10.5152/tud.2023.23030.
  15. Kim H.Y., Lim D., Choi Y.H., Yoo J.M., Lee D.S., Lee S.J. Efficacy of fosfomycin compared to second generation cephalosporin flumarin as antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: a single center retrospective study. BMC Urol. 2023;23(1):211. doi: 10.1186/s12894-023-01391-7.
  16. Pilatz A., Alidjanov J., Bonkat G., Wagenlehner F. Prostate biopsy-infection prophylaxis and patient preparation. Urologie. 2023;62(5):459–463. doi: 10.1007/s00120-023-02065-w. Epub 2023 Mar 7.
  17. Van Besien J., Uvin P., Weyne E., Van Praet C., Merckx L., De Graeve N., Van Renterghem K., Cartuyvels R., Van den Abeele A.M. Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: A prospective randomized study. Int J Urol. 2019;26(3):391–397. doi: 10.1111/iju.13883. Epub 2018 Dec 26.
  18. G. Bonkat (Chair), R. Bartoletti, F. Bruyère, T. Cai, S.E. Geerlings, B. Köves, J. Kranz, S. Schubert, A. Pilatz, R. Veeratterapillay, F. Wagenlehner Guidelines Associates: K. Bausch, W. Devlies, J. Horváth, L. Leitner, G. Mantica, T. Mezei Guidelines Office: E.J. Smith, H. Ali. EAU Guidelines on Urological Infections. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media